Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company's lead development candidate for osteoarthritis pain.

The advancement of LT-100 to GMP production marks the next step in the Company's strategy to administer LT-100 (pure honeybee venom) as a single subcutaneous injection per visit – a patient-centric approach compared to the 15 intradermal injections per treatment used in prior efficacy trials.